Abilify (aripiprazole) is a prescription medication used to treat several psychiatric conditions, including schizophrenia, bipolar disorder, and major depression. It belongs to a class of drugs called atypical antipsychotics, but its uses extend well beyond psychosis. It is one of the most widely prescribed psychiatric medications in the United States, approved for use in both adults and children depending on the condition.
FDA-Approved Uses in Adults
Abilify is approved for three primary conditions in adults. The first is schizophrenia, where it is used both to manage active symptoms and to prevent relapse in people who have already stabilized. The second is bipolar I disorder, specifically for manic or mixed episodes. It can be used on its own or alongside mood stabilizers like lithium or valproate for bipolar mania.
The third approved use is as an add-on treatment for major depressive disorder (MDD). Abilify is not prescribed as a standalone antidepressant. Instead, it is added when a standard antidepressant alone is not providing enough relief. For this purpose, it is started at a lower dose, typically 2 to 5 mg per day, compared to the 10 to 15 mg used for schizophrenia or bipolar disorder.
Approved Uses in Children and Adolescents
Abilify has four FDA-approved uses in younger patients, each with specific age requirements:
- Schizophrenia: approved for adolescents ages 13 to 17
- Bipolar I disorder (manic or mixed episodes): approved for ages 10 to 17
- Irritability associated with autism: approved for ages 6 to 17
- Tourette’s disorder: approved for ages 6 to 18
The autism indication is worth noting because Abilify does not treat autism itself. It targets specific behavioral symptoms like aggression, self-injury, severe tantrums, and rapid mood changes that can accompany autism spectrum disorder. Similarly, for Tourette’s, the medication helps reduce the frequency and severity of tics.
Off-Label Uses
Clinicians sometimes prescribe Abilify for conditions beyond its official approvals. It has shown efficacy in several studies for obsessive-compulsive disorder (OCD), particularly as an add-on when first-line treatments are not working well enough. It is also prescribed for anxiety and panic disorders in some cases. These uses are not FDA-approved, which means the evidence base is smaller, but they reflect real clinical practice.
How Abilify Works Differently From Other Antipsychotics
Most antipsychotic medications work by blocking dopamine receptors in the brain. Abilify takes a different approach. It acts as a partial agonist at dopamine receptors, meaning it can both activate and block these receptors depending on the situation. When dopamine levels are too high (as in psychosis or mania), it dials activity down. When dopamine levels are too low (as in some symptoms of depression or the “negative” symptoms of schizophrenia like emotional flatness), it provides a modest boost.
This stabilizing effect is sometimes described as a “dopamine system stabilizer.” Abilify also partially activates certain serotonin receptors, which contributes to its antidepressant effects and helps explain why it causes fewer movement-related side effects than older antipsychotics. The combination of these two mechanisms gives it a broader clinical profile than drugs that simply block dopamine.
How Long It Takes to Work
Abilify reaches steady levels in your bloodstream within about 14 days, so most prescribers will not adjust your dose before that two-week mark. But the timeline for feeling a noticeable difference depends on what you are taking it for.
Clinical trials for schizophrenia measured outcomes over 4 to 6 weeks. For bipolar mania, trials ran 3 to 4 weeks. For depression (as an add-on), the studies tracked patients over 6 weeks. For irritability in autism and Tourette’s disorder, trials lasted 8 to 10 weeks. These timelines give a rough idea of how long it takes for the full benefit to emerge, though some people notice changes sooner. If your dose needs adjusting for depression, autism-related irritability, or Tourette’s, changes are typically made no more frequently than once per week.
Common Side Effects
One of the most talked-about side effects of Abilify is akathisia, an uncomfortable inner restlessness that makes you feel like you need to keep moving. Antipsychotic-induced akathisia affects roughly 14% to 35% of people taking antipsychotic medications as a class, and Abilify is no exception. It can feel like anxiety or agitation, which sometimes leads to the symptom being confused with the condition being treated. If you experience a persistent urge to pace, fidget, or shift your weight, that is worth reporting to your prescriber.
Weight gain is another concern with any atypical antipsychotic, but Abilify generally causes less weight gain than alternatives like olanzapine. Some research has even shown that switching to Abilify from olanzapine can lead to weight loss and improved metabolic markers. That said, it is not completely weight-neutral. Studies in people taking it as an add-on for depression did find that it could contribute to weight gain in that population. The lower metabolic and cardiovascular risk compared to other drugs in its class is one of the reasons prescribers often favor it.
Other common side effects include nausea, insomnia, dizziness, and headache. These often improve during the first few weeks as your body adjusts to the medication.
Important Safety Warnings
Abilify carries two boxed warnings from the FDA, the most serious type of safety alert. The first applies to elderly patients with dementia-related psychosis: antipsychotic medications as a class increase the risk of death in this population, and Abilify is not approved for this use.
The second warning relates to suicidal thoughts and behavior. Because Abilify is approved as an add-on to antidepressants, it falls under the same warning that applies to antidepressant therapy. Short-term studies found an increased risk of suicidal thinking in children, adolescents, and young adults under 25. This risk was not seen in adults over 24, and patients 65 and older actually showed a reduced risk. Close monitoring is recommended during the early weeks of treatment and whenever the dose changes, particularly in younger patients. Family members and caregivers play an important role in watching for mood or behavior changes during this period.
Available Forms
Abilify comes in several formulations: oral tablets, orally disintegrating tablets, an oral solution, and an injectable form. The injectable version is used in hospital settings for acute agitation associated with schizophrenia or bipolar mania, where clinical trials showed measurable effects within 24 hours. A long-acting injectable version (Abilify Maintena) is also available for maintenance treatment of schizophrenia, given once monthly for people who prefer not to take daily pills or who have difficulty with medication adherence.